Figure 4: Overview of the Four Vaccine Platform Technologies Considered by Operation Warp Speed, as of January 2021
This image is excerpted from a U.S. GAO report:
www.gao.gov/products/GAO-21-319
OPERATION WARP SPEED: Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges
Note: Asterisk (*) indicates company has received an emergency use authorization (EUA), which allows the temporary use of an unlicensed vaccine, provided certain statutory criteria are met. As of January 2021, phase 3 clinical trials are still ongoing for these COVID-19 vaccine candidates, and the candidates are expected to ultimately be reviewed and receive licensure through a biologics license application, according to Food and Drug Administration (FDA) guidance.
Figure 4: Overview of the Four Vaccine Platform Technologies Considered by Operation Warp Speed, as of January 2021
This image is excerpted from a U.S. GAO report:
www.gao.gov/products/GAO-21-319
OPERATION WARP SPEED: Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges
Note: Asterisk (*) indicates company has received an emergency use authorization (EUA), which allows the temporary use of an unlicensed vaccine, provided certain statutory criteria are met. As of January 2021, phase 3 clinical trials are still ongoing for these COVID-19 vaccine candidates, and the candidates are expected to ultimately be reviewed and receive licensure through a biologics license application, according to Food and Drug Administration (FDA) guidance.